Michael Somero

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

Oliver A. Cornely, Derrick W. Crook, Roberto Esposito et al. · The Lancet Infectious Diseases · 2012 · 739 citations

Fidaxomicin Versus Vancomycin, Antimicrobial Susceptibility, Health Sciences +8

Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV

Julian Falutz, Soraya Allas, K Blot et al. · New England Journal of Medicine · 2007 · 306 citations · Full text

Early Microbiological Response to Linezolid vs Vancomycin in Ventilator-Associated Pneumonia Due to Methicillin-Resistant Staphylococcus aureus

Richard G. Wunderink, Meryl H. Mendelson, Michael Somero et al. · CHEST Journal · 2008 · 101 citations

Microbiological Response, Methicillin-resistant Staphylococcus Aureus, Health Sciences +10

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Julian Falutz, Diane Potvin, Jean‐Claude Mamputu et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 73 citations

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

Julian Falutz, Soraya Allas, Jean‐Claude Mamputu et al. · AIDS · 2008 · 65 citations